You're signed outSign in or to get full access.

Neuphoria Therapeutics (NEUP)

Period--

H--

L--

placeholder

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Neuphoria Therapeutics.

Q3 2025

Executives

Executive leadership at Neuphoria Therapeutics.

Spyros Papapetropoulos

President and Chief Executive Officer

Tim Cunningham

Chief Financial Officer

Board Members

Board of directors at Neuphoria Therapeutics.

Alan Fisher

Non-Executive Chair of the Board

David Wilson

Director

Jane Ryan

Director

Miles Davies

Director

Analyst Coverage

Research analysts covering Neuphoria Therapeutics.

Latest news

Recent press releases and 8-K filings for NEUP.

Neuphoria Therapeutics Inc. Reports Failed Phase 3 Trial for BNC210 and Initiates Strategic Review

NEUP

New Projects/Investments

Guidance Update

Neuphoria Therapeutics Inc.'s AFFIRM-1 Phase 3 trial evaluating BNC210 for the acute treatment of social anxiety disorder did not meet its primary or secondary endpoints.
As a result, the company will discontinue further development of its social anxiety disorder (SAD) program and plans to conduct a full strategic review of its operations and portfolio.
As of June 30, 2025, Neuphoria reported $14.2 million in cash and cash equivalents, which is expected to fund operations through the second fiscal quarter of 2027.

Oct 20, 2025, 8:15 PM

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Spyros Papapetropoulos say about margins?What are Neuphoria Therapeutics's strategic priorities?How is Neuphoria Therapeutics positioned vs competitors?How did Neuphoria Therapeutics do last quarter?